Header

UZH-Logo

Maintenance Infos

The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings


Riera, Joan; Hyttel-Sorensen, Simon; Bravo, María Carmen; Cabañas, Fernando; López-Ortego, Paloma; Sanchez, Laura; Ybarra, Marta; Dempsey, Eugene; Greisen, Gorm; Austin, Topun; Claris, Olivier; Fumagalli, Monica; Gluud, Christian; Lemmers, Petra; Pichler, Gerhard; Plomgaard, Anne Mette; van Bel, Frank; Wolf, Martin; Pellicer, Adelina (2016). The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings. Archives of Disease in Childhood. Fetal and Neonatal Edition, 101(4):F333-F338.

Abstract

BACKGROUND The SafeBoosC phase II randomised clinical trial recently demonstrated the benefits of a combination of cerebral regional tissue oxygen saturation (rStO2) by near-infrared spectroscopy (NIRS) and a treatment guideline to reduce the oxygen imbalance in extremely preterm infants. AIMS To analyse rStO2-alarm-related clinical decisions and their heterogeneity in the NIRS experimental group (NIRS monitoring visible) and their impact on rStO2 and SpO2. METHODS Continuous data from NIRS devices and the alarms (area under the curve of the rStO2 out of range had accumulated 0.2%h during 10 min), clinical data at discrete time points and interventions prompted by the alarms were recorded. RESULTS Sixty-seven infants had data that fulfilled the requirements for this analysis. 1107 alarm episodes were analysed. The alarm triggered a treatment guideline intervention in 25% of the cases; the type of intervention chosen varied among clinical sites. More than 55% of alarms were not followed by an intervention ('No action'); additionally, in 5% of alarms the rStO2 value apparently was considered non-reliable and the sensor was repositioned. The percentage of unresolved alarms at 30 min after 'No action' almost doubled the treatment guideline intervention (p<0.001). Changes in peripheral oxygen saturation (SpO2), were observed only after treatment guideline interventions. CONCLUSIONS This study shows that 25% of rStO2 alarms were followed by a clinical intervention determined by the treatment guideline. However, the rStO2 and SpO2 returned to normal ranges after the intervention, supporting the notion that decisions taken by the clinicians were appropriate. TRIAL REGISTRATION NUMBER ClinicalTrial.gov NCT01590316.

Abstract

BACKGROUND The SafeBoosC phase II randomised clinical trial recently demonstrated the benefits of a combination of cerebral regional tissue oxygen saturation (rStO2) by near-infrared spectroscopy (NIRS) and a treatment guideline to reduce the oxygen imbalance in extremely preterm infants. AIMS To analyse rStO2-alarm-related clinical decisions and their heterogeneity in the NIRS experimental group (NIRS monitoring visible) and their impact on rStO2 and SpO2. METHODS Continuous data from NIRS devices and the alarms (area under the curve of the rStO2 out of range had accumulated 0.2%h during 10 min), clinical data at discrete time points and interventions prompted by the alarms were recorded. RESULTS Sixty-seven infants had data that fulfilled the requirements for this analysis. 1107 alarm episodes were analysed. The alarm triggered a treatment guideline intervention in 25% of the cases; the type of intervention chosen varied among clinical sites. More than 55% of alarms were not followed by an intervention ('No action'); additionally, in 5% of alarms the rStO2 value apparently was considered non-reliable and the sensor was repositioned. The percentage of unresolved alarms at 30 min after 'No action' almost doubled the treatment guideline intervention (p<0.001). Changes in peripheral oxygen saturation (SpO2), were observed only after treatment guideline interventions. CONCLUSIONS This study shows that 25% of rStO2 alarms were followed by a clinical intervention determined by the treatment guideline. However, the rStO2 and SpO2 returned to normal ranges after the intervention, supporting the notion that decisions taken by the clinicians were appropriate. TRIAL REGISTRATION NUMBER ClinicalTrial.gov NCT01590316.

Statistics

Citations

Altmetrics

Downloads

24 downloads since deposited on 18 Jan 2016
7 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neonatology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2016
Deposited On:18 Jan 2016 15:33
Last Modified:07 Aug 2017 03:09
Publisher:BMJ Publishing Group
ISSN:1359-2998
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1136/archdischild-2015-308829
PubMed ID:26645538

Download

Download PDF  'The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings'.
Preview
Content: Published Version
Filetype: PDF
Size: 709kB
View at publisher